Published in Neuroimage Clin on March 05, 2013
Implications for Management of PET Amyloid Classification Technology (IMPACT) | NCT02778971
Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain (2015) 1.58
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging (2013) 1.14
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin (2013) 1.02
Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther (2015) 0.92
Type 2 diabetes as a protein misfolding disease. Trends Mol Med (2015) 0.91
Decreased Default Mode Network connectivity correlates with age-associated structural and cognitive changes. Front Aging Neurosci (2014) 0.91
Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry (2014) 0.89
Amyloid PET imaging: applications beyond Alzheimer's disease. Clin Transl Imaging (2015) 0.88
Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab (2014) 0.88
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurol (2016) 0.87
Multi-resolution statistical analysis of brain connectivity graphs in preclinical Alzheimer's disease. Neuroimage (2015) 0.85
Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. J Neuropathol Exp Neurol (2014) 0.84
The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement (2015) 0.84
Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease. Mov Disord (2015) 0.81
Targeting Metal-Aβ Aggregates with Bifunctional Radioligand [(11)C]L2-b and a Fluorine-18 Analogue [(18)F]FL2-b. ACS Med Chem Lett (2014) 0.81
Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Alzheimers Dement (Amst) (2015) 0.79
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information. Alzheimers Dement (Amst) (2016) 0.79
Early-Phase 11C-PiB PET in Amyloid Angiopathy-Related Symptomatic Cerebral Hemorrhage: Potential Diagnostic Value? PLoS One (2015) 0.77
Prefrontal Lobe Brain Reserve Capacity with Resistance to Higher Global Amyloid Load and White Matter Hyperintensity Burden in Mild Stage Alzheimer's Disease. PLoS One (2016) 0.76
Can insulin signaling pathways be targeted to transport Aβ out of the brain? Front Aging Neurosci (2015) 0.76
Automated synthesis of 18F-fluoropropoxytryptophan for amino acid transporter system imaging. Biomed Res Int (2014) 0.76
Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. Front Neurol (2017) 0.75
Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. J Int Neuropsychol Soc (2016) 0.75
RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. Transl Psychiatry (2016) 0.75
Unfolding Novel Mechanisms of Polyphenol Flavonoids for Better Glycaemic Control: Targeting Pancreatic Islet Amyloid Polypeptide (IAPP). Nutrients (2017) 0.75
On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther (2017) 0.75
Augmenting Amyloid PET Interpretations With Quantitative Information Improves Consistency of Early Amyloid Detection. Clin Nucl Med (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc (2002) 9.81
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging (1997) 7.54
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol (1988) 5.18
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology (2010) 2.92
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
[Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam (1968) 2.54
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology (2012) 2.49
APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology (2009) 2.27
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol (2012) 2.20
Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain (2007) 2.17
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol (2010) 2.15
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol (2013) 2.03
Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology (2012) 2.01
Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology (2010) 1.99
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia (2012) 1.90
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol (2006) 1.81
Alzheimer's disease: progress in prediction. Lancet Neurol (2010) 1.66
Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64
Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol (2012) 1.64
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia (2011) 1.62
Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia (2011) 1.60
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. Nat Rev Neurol (2013) 1.54
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Arch Neurol (2012) 1.52
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging (2012) 1.49
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci (2012) 1.48
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol (2009) 1.45
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol (2011) 1.40
Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain (2011) 1.39
Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging (2011) 1.37
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol (2011) 1.32
Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol (2011) 1.32
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging (2010) 1.30
Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology (2012) 1.27
Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology (2011) 1.26
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain (2011) 1.23
Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain (2010) 1.22
Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology (2011) 1.21
Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp (2012) 1.17
Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain (2010) 1.17
PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry (2010) 1.16
Toward a multifactorial model of Alzheimer disease. Neurobiol Aging (2012) 1.16
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem (2006) 1.16
Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol (2011) 1.12
Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. Arch Neurol (2012) 1.11
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol (2011) 5.01
Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport (2002) 3.31
Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol (2009) 2.83
Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci (2008) 2.15
What does transient global amnesia really mean? Review of the literature and thorough study of 142 cases. Brain (2006) 2.05
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain (2003) 1.72
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med (2009) 1.65
Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology (2008) 1.64
Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging (2007) 1.64
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2011) 1.57
Working memory and executive functions in transient global amnesia. Brain (2003) 1.53
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain (2009) 1.50
FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase (2005) 1.49
Semantic and episodic memory of music are subserved by distinct neural networks. Neuroimage (2003) 1.49
A combined neuropsychological and brain imaging study of obstructive sleep apnea. J Sleep Res (2009) 1.49
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci (2012) 1.48
TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain (2011) 1.46
Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain (2010) 1.44
Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol (2007) 1.42
A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain (2006) 1.36
The relationships between memory systems and sleep stages. J Sleep Res (2005) 1.35
Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. Neuroimage (2010) 1.34
Hippocampal activation for autobiographical memories over the entire lifetime in healthy aged subjects: an fMRI study. Cereb Cortex (2007) 1.33
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. Neurobiol Aging (2008) 1.31
Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging (2013) 1.30
The default mode network in healthy aging and Alzheimer's disease. Int J Alzheimers Dis (2011) 1.27
Episodic and semantic remote autobiographical memory in ageing. Memory (2002) 1.24
Episodic autobiographical memories over the course of time: cognitive, neuropsychological and neuroimaging findings. Neuropsychologia (2009) 1.23
Autobiographical memory and autonoetic consciousness: triple dissociation in neurodegenerative diseases. Brain (2003) 1.22
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain (2002) 1.20
Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat (2007) 1.20
Anatomical and functional alterations in semantic dementia: a voxel-based MRI and PET study. Neurobiol Aging (2006) 1.20
CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet (2007) 1.20
Autobiographical memory, autonoetic consciousness, and self-perspective in aging. Psychol Aging (2006) 1.17
Re-experiencing old memories via hippocampus: a PET study of autobiographical memory. Neuroimage (2004) 1.17
Consolidation of strictly episodic memories mainly requires rapid eye movement sleep. Sleep (2004) 1.15
Genuine episodic memory deficits and executive dysfunctions in alcoholic subjects early in abstinence. Alcohol Clin Exp Res (2007) 1.12
Is there a link between sleep changes and memory in Alzheimer's disease? Neuroreport (2008) 1.12
Effect of episodic and working memory impairments on semantic and cognitive procedural learning at alcohol treatment entry. Alcohol Clin Exp Res (2007) 1.11
Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation. EMBO Mol Med (2011) 1.11
Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. Acta Neuropathol (2010) 1.10
Detecting hippocampal hypometabolism in Mild Cognitive Impairment using automatic voxel-based approaches. Neuroimage (2007) 1.09
Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. Neuroimage (2013) 1.08
Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener (2012) 1.08
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol (2009) 1.08
Convergence between lesion-symptom mapping and functional magnetic resonance imaging of spatially selective attention in the intact brain. J Neurosci (2008) 1.07
Abeta amyloid deposition in the language system and how the brain responds. Brain (2007) 1.05
Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia. Neuroimage Clin (2013) 1.04
Characterization of ubiquitinated intraneuronal inclusions in a novel Belgian frontotemporal lobar degeneration family. J Neuropathol Exp Neurol (2006) 1.04
Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol (2013) 1.04
DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiol Aging (2011) 1.02
Autoimmune-mediated encephalitis. Neuroradiology (2011) 1.01
When music and long-term memory interact: effects of musical expertise on functional and structural plasticity in the hippocampus. PLoS One (2010) 1.00
C9orf72 G4C2 repeat expansions in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2013) 1.00
Age effect on the default mode network, inner thoughts, and cognitive abilities. Neurobiol Aging (2012) 0.99
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology (2013) 0.99
Spoken word memory traces within the human auditory cortex revealed by repetition priming and functional magnetic resonance imaging. J Neurosci (2008) 0.98
When the zebra loses its stripes: Semantic priming in early Alzheimer's disease and semantic dementia. Cortex (2009) 0.98
Lesion evidence for the critical role of the intraparietal sulcus in spatial attention. Brain (2011) 0.98
Mental time travel into the past and the future in healthy aged adults: an fMRI study. Brain Cogn (2010) 0.97
Lesion neuroanatomy of the Sustained Attention to Response task. Neuropsychologia (2009) 0.97
Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association. J Alzheimers Dis (2010) 0.96
Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients. Neurobiol Aging (2013) 0.95
Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol Aging (2011) 0.95
Study of metamemory in patients with chronic alcoholism using a feeling-of-knowing episodic memory task. Alcohol Clin Exp Res (2010) 0.94
Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis (2012) 0.94
Executive functioning and judgment-of-learning versus feeling-of-knowing in older adults. Exp Aging Res (2003) 0.93
Working memory and FDG-PET dissociate early and late onset Alzheimer disease patients. J Neurol (2005) 0.93
Relationships between brain metabolism decrease in normal aging and changes in structural and functional connectivity. Neuroimage (2013) 0.92
Changes in the episodic memory and executive functions of abstinent and relapsed alcoholics over a 6-month period. Alcohol Clin Exp Res (2008) 0.92
Attentional priorities and access to short-term memory: parietal interactions. Neuroimage (2012) 0.91
Changes in sleep theta rhythm are related to episodic memory impairment in early Alzheimer's disease. Biol Psychol (2011) 0.91
Which processes are involved in cognitive procedural learning? Memory (2006) 0.91
Autonoetic consciousness in Alzheimer's disease: neuropsychological and PET findings using an episodic learning and recognition task. Neurobiol Aging (2006) 0.91
Episodic and working memory deficits in alcoholic Korsakoff patients: the continuity theory revisited. Alcohol Clin Exp Res (2008) 0.91
Gesture discrimination in primary progressive aphasia: the intersection between gesture and language processing pathways. J Neurosci (2010) 0.90
Metabolic and structural connectivity within the default mode network relates to working memory performance in young healthy adults. Neuroimage (2013) 0.90
What happens to personal identity when semantic knowledge degrades? A study of the self and autobiographical memory in semantic dementia. Neuropsychologia (2011) 0.90